Zalutumumab in Head and Neck Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of squamous cell carcinoma of the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx or larynx. * Primary or recurrent disease for which no curative or established palliative treatments are amenable * WHO performance status of 1 or 2. Exclusion Criteria: * Received certain other treatments within 4 weeks prior to administration of study drug * Previous severe allergic reactions (e.g. angio-edema, severe asthma, or anaphylaxis). * Skin disease requiring systemic or local corticosteroid therapy. * Known brain metastasis or leptomeningeal disease. * Signs or symptoms of acute illness. * Bacterial, fungal or viral infection. * Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, myocardial infarction within one year and stomach, lung, heart, hormonal, nerve or blood diseases. * Pregnant or breast-feeding women. * Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial. * Simultaneous participation in any other trial involving investigational drugs or having participated in a trial within 4 weeks prior to start of trial treatment.